Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

NCT01767155 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

511

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: AEZS-108 / zoptarelin doxorubicin
DRUG: doxorubicin

Sponsor

AEterna Zentaris